-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network Market Analysis: Recently, industry sources said that the board of directors of a foreign company in China decided that the company's sales department will implement the transformation of marketing model, from direct business model to product promotion and marketing service outsourcing investment modelIn general, after the transition period, the sales staff will be all transformed, no longer have a base salary and five insurance one goldIf you do not accept this arrangement, you can transfer to the headquarters to work, do not transfer, in accordance with the N1 termination of the labor contract
It is understood that a number of medical representatives have accepted compensation, ready to leave
In fact, there have been recent reports that pharmaceutical companies are cutting sales teams or that sales teams are going to cut their salariesAs in the past, a domestic pharmaceutical company issued a notice that due to the operating situation, the dissolution of a product line, the abolition of more than 50 people
These news have caused widespread concern and discussion in the industry, mainly because of this special period, due to the impact of pharmaceutical business activities, the first quarter of the performance is not ideal, many pharmaceutical practitioners have concerns and worries about their career prospectsBut in this regard, there are also industry insiders said that these drug companies to cut the sales team, may still be because of their own internal situation
In February-March, for example, Mercado divested women's health products, mature products and biosimilars to set up a new company; Sanofi merged six API production sites in Europe to create an independent API company and announced plans to spin off its consumer health business; and GSK proposed to spin off some of its antibiotic businessAll of this will lead to a number of medical representatives of the post changes
In fact, some industry experts said that by the influence of many factors, pharmaceutical representatives are not optimistic about the current situation, such as by the volume procurement and other health care reform policies, drug prices are becoming an industry trend, in the middle of the situation is squeezed, many pharmaceutical companies will be seriously reduced costs of pharmaceutical representatives included in the team of layoffs
For example, in the collection and expansion, the unbid Beijing Jialin Pharmaceuticals announced the dissolution of its sales team shortly afterwards, and the multinational drug company Sanofi optimized the diversion of Bolewi's medical team and sales teamIn addition, there are a number of enterprises before the news to adjust the sales department, such as at the beginning of this year, Watson Pharmaceuticals, Enhua Pharmaceuticals, Hengrui Pharmaceuticals and many other well-known pharmaceutical companies have already made adjustments to the sales department, and even clearly will reduce the investment in the sales sector
It can be said that the policy requirements of 4 plus 7 band quantity procurement, medical insurance control fees and so on, in the pharmaceutical enterprises and pharmaceutical representatives have been constantly testing the ability to resist risksIn recent years, it can be clearly seen that more and more domestic pharmaceutical companies are through innovative research and development, change the sales model and so on to increase market competitivenessFor example, innovative drugs can reduce the negative impact of administrative drug price reduction, some pharmaceutical companies began to gradually move to innovative drug research and developmentBrukina, a BTK inhibitor developed by Baiji Shenzhou, has now been accelerated by the FDA, not only breaking through the domestic market's shrinking profits, but also bringing a "zero breakthrough" to China's new drug research
Industry insiders said that in the long run, the core product competitive advantage is obvious, product diversification and research and development capabilities outstanding pharmaceutical manufacturing enterprises and have a sound sales network layout and channel construction of pharmaceutical circulation enterprises will maintain a stronger competitive advantage and risk resistance in the future
In general, in China's pharmaceutical market, some sub-sectors of niche drugs still need to be learned and excavated, even if these drugs in the relative number of minority, but given China's large number of patients, the number is not smallIn the future, medical representatives will not disappear, but will return to the standard and value upgradeAs a pharmaceutical representative itself needs to continuously improve their own quality, calmly face the development of the industry and unexpected circumstances bring about changes.